Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib
Author:
Affiliation:
1. Janssen Research & Development Beerse Belgium
2. Janssen Research & Development Spring House Pennsylvania USA
3. Janssen‐Cilag SpA Cologno Monzese Italy
4. Janssen Research & Development, LLC Raritan New Jersey USA
Funder
Janssen Research and Development
Publisher
Wiley
Subject
Pharmacology (medical),Modeling and Simulation
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12682
Reference32 articles.
1. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
2. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
3. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
4. BALVERSATM. Prescribing information. Horsham PA: Janssen Products LP; 2019.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf. Accessed December 15 2020.
5. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. In vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692;European Journal of Pharmaceutical Sciences;2024-01
2. Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults – an AGePOP review;European Journal of Pharmaceutical Sciences;2023-09
3. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs;Cancer Chemotherapy and Pharmacology;2023-07-19
4. Beyond the Michaelis–Menten : Accurate Prediction of Drug Interactions Through Cytochrome P450 3A4 Induction;Clinical Pharmacology & Therapeutics;2023-01-11
5. The Blind Spot of Pharmacology: A Scoping Review of Drug Metabolism in Prematurely Born Children;Frontiers in Pharmacology;2022-02-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3